NYSEAMERICAN:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CATX Stock Alerts 1.80 +0.04 (+2.27%) (As of 06:18 PM ET) Add Compare Share Share Today's Range1.73▼1.8350-Day Range N/A52-Week Range0.21▼1.90Volume6.02 million shsAverage Volume3.94 million shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Perspective Therapeutics alerts: Email Address Perspective Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.06Based on 10 Articles This WeekInsider TradingAcquiring Shares$57.41 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom -0.09 to -0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.27 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Perspective Therapeutics.Read more about Perspective Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.24% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 28.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CATX. Previous Next 1.7 News and Social Media Coverage News SentimentPerspective Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Perspective Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -73% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought 57,409,487.00 in company stock and sold 0.00 in company stock.Percentage Held by InsidersOnly 3.52% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from -0.09 to -0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Perspective Therapeutics is -18.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Perspective Therapeutics is -18.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Perspective Therapeutics Stock (NYSEAMERICAN:CATX)Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Read More CATX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CATX Stock News HeadlinesMay 9, 2024 | msn.comCantor Fitzgerald Initiates Coverage of Perspective Therapeutics (CATX) with Overweight RecommendationMay 9, 2024 | americanbankingnews.comPerspective Therapeutics (NYSEAMERICAN:CATX) Stock Rating Reaffirmed by Lifesci CapitalMay 9, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.May 4, 2024 | americanbankingnews.comPerspective Therapeutics (NYSEAMERICAN:CATX) Hits New 12-Month High at $1.87May 3, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming May Investor ConferencesMay 2, 2024 | markets.businessinsider.comThe Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 ExpertsMay 2, 2024 | finance.yahoo.comPerspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comPerspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsMay 9, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 30, 2024 | globenewswire.comPerspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETsApril 8, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming April Investor ConferencesMarch 28, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsMarch 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Perspective Therapeutics Amid Clinical Success and Strategic PartnershipsMarch 19, 2024 | wsj.comPerspective Therapeutics Inc.March 18, 2024 | msn.comPerspective Therapeutics partners with Bristol Myers for its metastatic melanoma treatment studyMarch 18, 2024 | finance.yahoo.comPerspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic MelanomaMarch 12, 2024 | msn.comenGene Holdings GAAP EPS of -$0.46March 11, 2024 | finance.yahoo.comPerspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024March 7, 2024 | bizjournals.comPerspective Therapeutics raises $87 million on heels of big January roundMarch 4, 2024 | globenewswire.comPerspective Therapeutics Announces $87.4 Million Private PlacementFebruary 26, 2024 | finance.yahoo.comPerspective Therapeutics to Participate at Upcoming Investor ConferencesFebruary 13, 2024 | finance.yahoo.comPTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings GrowthFebruary 12, 2024 | finance.yahoo.comPerspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | msn.comPerspective Therapeutics Updates Corporate Presentation OnlineFebruary 1, 2024 | finance.yahoo.comPerspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology PlatformFebruary 1, 2024 | finance.yahoo.comHeybike Will Soon Release Hero -- A Powerful All-Terrain E-bikeJanuary 29, 2024 | msn.comPerspective Therapeutics And 3 Other Stocks Under $2 Insiders Are BuyingSee More Headlines Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSEAMERICAN:CATX CUSIPN/A CIKN/A Webwww.isoray.com Phone(509) 375-1202Fax509-267-3670Employees116Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)-0.10 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,510,000.00 Net Margins-302.70% Pretax Margin-3,428.10% Return on Equity-46.44% Return on Assets-40.78% Debt Debt-to-Equity Ratio0.02 Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual Sales$1.43 million Price / Sales738.78 Cash FlowN/A Price / Cash FlowN/A Book Value0.27 per share Price / Book6.67Miscellaneous Outstanding Shares586,920,000Free Float566,257,000Market Cap$1.06 billion OptionableNot Optionable Beta1.43 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Johan M. Spoor (Age 52)CEO & Director Comp: $855.78kMr. Jonathan R. Hunt (Age 57)CFO & Co-Principal Financial Officer Comp: $944.35kDr. Markus Puhlmann M.B.A. (Age 57)M.D., Chief Medical Officer Comp: $633.14kMr. Shane CobbExecutive Vice President of OperationsMr. Mark J. Austin CPA (Age 37)VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary Dr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExecutive Vice President of BrachytherapyMr. Amos Hedt BAPGradDip, Chief Business Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Senior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsMiMedx GroupNASDAQ:MDXGAtriCureNASDAQ:ATRCParagon 28NYSE:FNAArtivionNYSE:AORTSilk Road MedicalNASDAQ:SILKView All CompetitorsInsiders & InstitutionsBleakley Financial Group LLCBought 33,570 shares on 5/8/2024Ownership: 0.006%RIA Advisory Group LLCBought 99,293 shares on 5/3/2024Ownership: 0.018%ZWJ Investment Counsel Inc.Bought 22,000 shares on 4/26/2024Ownership: 0.004%Simplicity Wealth LLCBought 33,570 shares on 4/24/2024Ownership: 0.006%Lantheus Alpha Therapy, LlcBought 60,431,039 shares on 3/6/2024Total: $57.41 M ($0.95/share)View All Insider TransactionsView All Institutional Transactions CATX Stock Analysis - Frequently Asked Questions Should I buy or sell Perspective Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perspective Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CATX shares. View CATX analyst ratings or view top-rated stocks. How have CATX shares performed in 2024? Perspective Therapeutics' stock was trading at 1.19 at the start of the year. Since then, CATX shares have increased by 51.3% and is now trading at 1.80. View the best growth stocks for 2024 here. Are investors shorting Perspective Therapeutics? Perspective Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 10,430,000 shares, an increase of 28.9% from the March 31st total of 8,090,000 shares. Based on an average daily volume of 4,090,000 shares, the days-to-cover ratio is presently 2.6 days. Currently, 2.2% of the company's shares are short sold. View Perspective Therapeutics' Short Interest. Who are Perspective Therapeutics' major shareholders? Perspective Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RIA Advisory Group LLC (0.02%), Bleakley Financial Group LLC (0.01%), Simplicity Wealth LLC (0.01%) and ZWJ Investment Counsel Inc. (0.00%). Insiders that own company stock include Jonathan Robert Hunt, Lantheus Alpha Therapy, Llc, Markus Puhlmann and Robert F Williamson III. View institutional ownership trends. This page (NYSEAMERICAN:CATX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 Media348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.